SAN FRANCISCO – The California Institute of Regenerative Medicine (CIRM) has awarded OSSM-007, an interferon-gamma primed mesenchymal stem cell product from Ossium Health, Inc., a USD 3.46 million Clinical Stage Research Programme (CLIN1) grant to support the company’s ongoing clinical development of OSSM-007 for the treatment of acute steroid-refractory graft versus host disease (GVHD). With expectations to start clinical study activities by the end of 2023, this financing will support and accelerate pre-clinical and manufacturing efforts for OSSM-007, among other things.
Following allogeneic hematopoietic stem cell transplants (HCT), an immune-competent donor cell graft will recognize and attack the recipient’s (host) tissues, resulting in cute GVHD. Acute GVHD affects 30–60% of allogeneic HCT recipients, and about 50% of these patients will not respond to systemic steroid therapy. GVHD continues to be a major cause of morbidity and mortality in allogeneic HCT recipients despite general improvements in other HCT outcomes, emphasizing the urgent need for efficient novel treatments.
After allogeneic hematopoietic stem cell transplants (HCT), immunocompetent donor cells (the graft) recognize and attack the recipient’s (host) tissues, resulting in acute GVHD. Acute GVHD affects 30–60% of allogeneic HCT recipients, and about 50% of these patients will not respond to systemic steroid therapy. GVHD continues to be a significant cause of morbidity and mortality in allogeneic HCT recipients despite general improvements in other HCT outcomes, emphasizing the urgent need for efficient novel treatments.
“We’re thrilled to partner with CIRM and appreciate their ongoing commitment to advancing research in stem cell-based therapeutics,” said Kevin Caldwell, Chief Executive Officer and Co-Founder of Ossium. This grant will hasten OSSM-007’s development at Ossium and is an essential first step toward a potential new therapeutic option for GVHD patients.
About the startup:
Ossium Health is a bioengineering business that uses its unique platform for banking bone marrow from deceased donors to create cell therapies that are being tested as cures for orthopedic injuries, organ rejection, and hematologic illnesses. Co-founders President & CEO Kevin Caldwell and EVP & Chief Science Officer Erik Woods are in charge of their 2016-founded business. The company aims to use bioengineering to increase human health, vitality, and longevity.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by! Next Article
 has awarded OSSM-007, an interferon-gamma primed mesenchymal stem cell product from Ossium Health, Inc., a USD 3.46 million Clinical Stage Research Programme (CLIN1) grant to support the company's ongoing clinical development of OSSM-007 for the treatment of acute steroid-refractory graft versus host disease (GVHD). With expectations to start clinical study activities by the end of 2023, this financing will support and accelerate pre-clinical and manufacturing efforts for OSSM-007, among other things.){kind=link}